全文获取类型
收费全文 | 935篇 |
免费 | 52篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 41篇 |
妇产科学 | 30篇 |
基础医学 | 124篇 |
口腔科学 | 24篇 |
临床医学 | 76篇 |
内科学 | 186篇 |
皮肤病学 | 14篇 |
神经病学 | 37篇 |
特种医学 | 28篇 |
外科学 | 147篇 |
综合类 | 9篇 |
预防医学 | 57篇 |
眼科学 | 26篇 |
药学 | 69篇 |
中国医学 | 7篇 |
肿瘤学 | 112篇 |
出版年
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 26篇 |
2020年 | 11篇 |
2019年 | 23篇 |
2018年 | 23篇 |
2017年 | 16篇 |
2016年 | 33篇 |
2015年 | 32篇 |
2014年 | 55篇 |
2013年 | 65篇 |
2012年 | 97篇 |
2011年 | 93篇 |
2010年 | 40篇 |
2009年 | 40篇 |
2008年 | 62篇 |
2007年 | 60篇 |
2006年 | 60篇 |
2005年 | 39篇 |
2004年 | 51篇 |
2003年 | 35篇 |
2002年 | 35篇 |
2001年 | 7篇 |
2000年 | 7篇 |
1999年 | 8篇 |
1998年 | 6篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有990条查询结果,搜索用时 31 毫秒
11.
12.
Sabnavis Sowmya Aruna Ramaiah Tella Sunitha Pratibha Nallari Akka Jyothy Ananthapur Venkateshwari 《Inflammation》2014,37(4):1022-1027
—Preeclampsia is a severe complication of pregnancy characterized by an excessive maternal systemic inflammatory response with activation of both the innate and adaptive immune system. Interleukin-10 affects maternal intravascular inflammation, as well as endothelial dysfunction. The aim of the study was to investigate the association between IL-10 T-819 C polymorphism and preeclampsia. A total of 120 pregnant women with preeclampsia and 120 women with normal pregnancy attending the Gynecological Unit of Government Maternity Hospital, Petlaburz, Hyderabad, India, were considered for the present study. A standard amplification refractory mutation system (ARMS) PCR was carried out for genotyping of IL-10 T-819 C promoter polymorphism in all the participants. Genotypic distribution of the control and patient groups was compared with values predicted by the Hardy-Weinberg equilibrium using χ2 test. Odds ratios (OR) and their respective 95 % confidence intervals were used to measure the strength of association between IL-10 gene polymorphism and preeclampsia. The frequencies of IL-10 T-819 C genotypes, CC, CT, and TT, were 47.5, 28.3, and 24.2 % in women with preeclampsia and 20.8, 48.3, and 30.8 % in the controls, respectively. There is a significant difference in the distribution of genotypes and alleles of IL-10 T-819 C between the two groups (test power?=?0.66). The present study suggests that the IL-10 T-819 C gene promoter polymorphism can be a major genetic regulator in the etiology of preeclampsia 相似文献
13.
Diagnosis and Management of Atypical Hemolytic Uremic Syndrome In Children: Single Centre Experience
Rashmi D. Patel Aruna V. Vanikar Manoj R. Gumber Kamal V. Kanodia Kamlesh S. Suthar Himanshu V. Patel Hargovind L. Trivedi 《Indian journal of hematology & blood transfusion》2014,30(4):342-346
Atypical hemolytic uremic syndrome (aHUS) although rare is the commonest cause of acute renal failure (ARF) in children and has poor prognosis. We present single centre experience of aHUS. Thirty six children (29 males, 7 females) with mean age, 7.9 years presented with ARF, 2 children also had tonic–clonic type convulsions. Their hematology examination revealed hemolytic anemia with s. creatinine (SCr), 5.54 mg/dl. Acute HUS was observed in 75 %, acute on chronic HUS in 19.4 % and patchy cortical necrosis (PCN) in 5.6 % biopsies. Mean 5.4 plasma exchanges (PE) were carried out. Supportive management of anti-hypertensives and prednisone was also given. Recovery end points were establishment of urine output, improvement of SCr and hematological profile. Hematology and renal function profile improved variably in all children, 5.6 % died, relapse was observed in 80.5 % over mean 70 days; 13.9 % children are doing well over mean follow-up of 268.8 days. Thus poor prognosis was observed in 86.1 % children. Children with acute on chronic HUS and PCN did not recover. Six children who recovered had acute HUS. aHUS in Indian children occurs at an older age of around 8 years and chronic/irreversible changes on histopathology examination are harbingers of poor prognosis. PE is life-saving however further research for developing strategies to improve long-term survival is needed. 相似文献
14.
Mohan P. Patel Vivek B. Kute Manoj R. Gumber Dinesh N. Gera Pankaj R. Shah Himanshu V. Patel Hargovind L. Trivedi Aruna V. Vanikar 《Parasitology research》2013,112(1):427-430
Plasmodium vivax infection is increasingly a major public health burden and the second most frequent human malaria. Higher levels of clinical severity and chloroquine resistance are major factors responsible for such increases. Malarial glomerular injury is uncommon and mainly observed in Plasmodium malariae-infected patients. Occasionally, transient immune complex-mediated glomerulonephritis is associated with Plasmodium falciparum infection. Coexistent crescentic glomerulonephritis and vivax malaria have not previously been reported. We report a fatal case of P. vivax malaria, who presented with acute renal failure. P. vivax monoinfection status was diagnosed with peripheral blood smear and rapid antigen test. Further evaluation for renal failure related to systemic illness and immunological markers were inconclusive. He was treated with antimalarial drugs, hemodialysis, and supportive therapy. Renal biopsy performed for nonrecovering renal failure reveled crescentic glomerulonephritis. This case highlights the need to thoroughly search for malaria-associated crescentic glomerulonephritis using renal biopsy after nonrecovering renal failure. 相似文献
15.
The conjugation of an AQP1-directed immunotoxin in the study of site-directed therapy within the CNS
Purpose
The water channel, aquaporin (AQP)1, is highly specific to the choroid plexus (CP) epithelium within the brain. It is therefore a potential target through which therapeutic agents could be selectively directed to the CP. Here we describe the conjugation of a monoclonal antibody (mAb), raised against an extra-cellular domain of AQP1, to the A chain of ricin (RCA). This reagent should allow study of a highly specific chemical lesion of the CP. 相似文献16.
17.
18.
Hanchen Xu Kevin Van der Jeught Zhuolong Zhou Lu Zhang Tao Yu Yifan Sun Yujing Li Changlin Wan Ka Man So Degang Liu Michael Frieden Yuanzhang Fang Amber L. Mosley Xiaoming He Xinna Zhang George E. Sandusky Yunlong Liu Samy O. Meroueh Chi Zhang Aruna B. Wijeratne Cheng Huang Guang Ji Xiongbin Lu 《The Journal of clinical investigation》2021,131(10)
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy. 相似文献
19.
Brendan M. Everett Marc Y. Donath Aruna D. Pradhan Tom Thuren Prem Pais Jose C. Nicolau Robert J. Glynn Peter Libby Paul M Ridker 《Journal of the American College of Cardiology》2018,71(21):2392-2401
Background
Subclinical inflammation mediated in part by interleukin (IL)-1β participates in peripheral insulin resistance and impaired pancreatic insulin secretion.Objectives
The authors tested the hypothesis that the IL-1β inhibitor canakinumab reduces incident diabetes.Methods
The authors randomized 10,061 patients with prior myocardial infarction and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/l to placebo or canakinumab at doses of 50 mg, 150 mg, or 300 mg subcutaneously once every 3 months. The authors tested the effects of canakinumab on major cardiovascular events in patients with and without diabetes at baseline, and evaluated as a pre-specified analysis whether canakinumab would reduce the risk of adjudicated cases of new-onset type 2 diabetes among those with protocol-defined pre-diabetes at trial entry. The authors also evaluated the effect of canakinumab on fasting plasma glucose and glycosylated hemoglobin (HbA1c) in patients with and without established diabetes.Results
Of the participants, 4,057 (40.3%) had baseline diabetes, 4,960 (49.3%) had pre-diabetes, and 1,044 (10.4%) had normal glucose levels. Among those without diabetes, increasing tertiles of hsCRP at baseline associated with an increased risk of developing diabetes during the median follow-up period of 3.7 years (incidence rates 3.2, 4.1, and 4.4 per 100 person-years; p = 0.003). Canakinumab 150 mg as compared with placebo had similar magnitude effects on major cardiovascular event rates among those with diabetes (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.70 to 1.03), pre-diabetes (HR: 0.86; 95% CI: 0.70 to 1.06), and normoglycemia (HR: 0.81; 95% CI: 0.49 to 1.35). Despite large reductions in hsCRP and IL-6, canakinumab did not reduce the incidence of new-onset diabetes, with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg canakinumab groups of 4.2, 4.2, 4.4, and 4.1, respectively (log-rank p = 0.84). The HR comparing all canakinumab doses to placebo was 1.02 (95% CI: 0.87 to 1.19; p = 0.82). Canakinumab reduced HbA1c during the first 6 to 9 months of treatment, but no consistent long-term benefits on HbA1c or fasting plasma glucose were observed.Conclusions
Although IL-1β inhibition with canakinumab had similar effects on major cardiovascular events among those with and without diabetes, treatment over a median period of 3.7 years did not reduce incident diabetes. (Canakinumab Anti-inflammatory Thrombosis Outcomes Study [CANTOS]; NCT01327846) 相似文献20.
Andrew E. Blum Srividya Venkitachalam Durgadevi Ravillah Aruna K. Chelluboyina Ann Marie Kieber-Emmons Lakshmeswari Ravi Adam Kresak Apoorva K. Chandar Sanford D. Markowitz Marcia I. Canto Jean S. Wang Nicholas J. Shaheen Yan Guo Yu Shyr Joseph E. Willis Amitabh Chak Vinay Varadan Kishore Guda 《Gastroenterology》2019,156(6):1761-1774